Skip to content

Clinical stduy of effects of ultrasonic guided stellate ganglion pulsed-radiofrequency on cervical and upper thoracic postherpetic neuralgia

Clinical stduy of effects of ultrasonic guided stellate ganglion pulsed-radiofrequency on cervical and upper thoracic postherpetic neuralgia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037329
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

experimental group:stellate ganglion pulsed-radiofrequency
control group:false pulsed-radiofrequency

Sponsors

Shanghai Xinhua Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) The subjects signed the informed consent of the trial voluntarily; 2) Patients with chronic herpes zoster neuralgia: aged 18 years or older and less than or equal to 80 years old, regardless of gender; 3) Patients with moderate or severe pain who have been treated with sensory nerve block at least once, but the effect is not good. Patients with vas > 4 scores or with burst pain > 3 times / day; 4) The patients were able to follow the drug dosage and visit plan; 5) Objective description of symptoms, no serious infection, respiratory insufficiency, etc., can actively cooperate; 6) No allergic disease and non allergic constitution; 7) Contraindications of non ropivacaine or other local anesthetic drugs; 8) There were no drug abusers or addicts; 9) Non lactating and pregnant women: subjects without pregnancy plan within 1 month after the trial (including male subjects); 10) Did not participate in the drug test (including the test drug) within 3 months before the trial.

Exclusion criteria

Exclusion criteria: 1) The general condition is poor, can not objectively describe the symptoms, or have serious infection, respiratory insufficiency, etc., can not actively cooperate; 2) Patients with severe respiratory system, cardiovascular system disease, liver and kidney dysfunction, malignant tumor; 3) Patients with allergic diseases and allergic constitution; those who are allergic to ropivacaine or other local anesthetic drugs; 4) Those who suspected or had a history of drug abuse and addiction; 5) Lactating and pregnant women: subjects without pregnancy plan within one month after the trial (including male subjects); 6) Patients who participated in the drug trial within 3 months before the trial (including the trial drug); 7) The sponsor or researcher directly involved in the trial or their family members; 8) The researchers thought that there was any reason why they could not be selected.

Design outcomes

Primary

MeasureTime frame
VAS score;

Countries

China

Contacts

Public ContactLiu Xiaoming

Shanghai Xinhua Hospital

12206913@qq.com+86 17721213706

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026